Internal Medicine, Medical Oncology · Philadelphia, PA
NPI
1831477710
Since 2011
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
925 Chestnut St Ste 320a
Philadelphia, PA, 19107
Phone (215) 955-8874
Groups this clinician bills Medicare through
Medicare paid, 2024
$56K
772 services
Medicare patients, 2024
165
Average age 72
Drug cost, 2024
$1.1M
497 prescriptions
Company payments, 2025
$3,508
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel Lin was code 99214 (office e&m - established), 315 times for 96 patients. In total Daniel Lin billed 772 services in 13 codes, and Medicare paid $56K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 315 | 96 | $75.54 | $24K |
| 36415 Venipuncture Blood Collection | Office | 113 | 25 | $8.57 | $969 |
| 99214 Office E&M - Established | Office | 100 | 44 | $95.68 | $9,568 |
| 99215 Office E&M - Established | Facility | 69 | 42 | $107.54 | $7,420 |
| 99205 Office E&M - New | Facility | 31 | 31 | $136.88 | $4,243 |
| 99213 Office E&M - Established | Office | 26 | 20 | $62.67 | $1,629 |
| 99213 Office E&M - Established | Facility | 21 | 17 | $50.63 | $1,063 |
| 99232 Hospital E&M - Subsequent | Facility | 19 | 13 | $63.32 | $1,203 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 18 | 13 | $25.26 | $455 |
| 99215 Office E&M - Established | Office | 15 | 11 | $134.20 | $2,013 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 14 | 14 | $13.23 | $185 |
By year: 2022 $39K for 466 services; 2023 $46K for 542 services; 2024 $56K for 772 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 113 | 25 | $8.57 | $969 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel Lin prescribed most often to Medicare patients was Prochlorperazine Maleate, with 60 prescriptions and refills. In total Daniel Lin wrote 497 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prochlorperazine Maleate Generic | 60 | 60 | 40 | $1,227 |
| Ondansetron Hcl Generic | 56 | 56 | 37 | $296 |
| Creon Lipase/Protease/Amylase | 51 | 60 | Under 11 | $118K |
| Eliquis Apixaban | 29 | 29 | Under 11 | $17K |
| Famotidine Generic | 26 | 44 | Under 11 | $216 |
| Potassium Chloride Generic | 17 | 17 | Under 11 | $123 |
| Cabometyx Cabozantinib S-Malate | 16 | 16 | Under 11 | $398K |
| Dicyclomine Hcl Generic | 15 | 17 | Under 11 | $225 |
| Loperamide Loperamide Hcl | 13 | 13 | Under 11 | $340 |
| Tramadol Hcl Generic | 12 | 12 | Under 11 | $29.21 |
| Udenyca Pegfilgrastim-Cbqv | 12 | 12 | Under 11 | $100K |
| Lenvima Lenvatinib Mesylate | 12 | 12 | Under 11 | $292K |
| Candesartan Cilexetil Generic | 12 | 26 | Under 11 | $1,004 |
| Lorazepam Generic | 12 | 12 | Under 11 | $91.48 |
Brand drugs: 138 claims; generic drugs: 359 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel Lin $3,508 ($3,508 in general payments such as food, travel and fees) from 8 companies. The largest payer was Incyte Corporation with $3,101.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.